Medicine Recommendations

All indications

Treatment of severe osteoporosis

- in postmenopausal women;

- in adult men

at high risk of fracture, for whom treatment with other medicinal products approved for the treatment of osteoporosis is not possible due to, for example, contraindications or intolerance. In postmenopausal women, strontium ranelate reduces the risk of vertebral and hip fractures.

The decision to prescribe strontium ranelate should be based on an assessment of the individual patient's overall risks

MHRA Drug Safety Update - Strontium ranelate: cardiovascular risk—restricted indication and new monitoring requirements (March 2014)

Radiation proctitis

Bile acid gastritis

Crohn's disease

Rheumatoid arthritis

Sero-negative spondyloarthropathy including psoriatic arthritis & psoriasis (unlicensed)

Ulcerative colitis

Cluster Headache

Psoriasis

 Psoriasis

For prophylaxis of graft rejection

Topical treatment for atopic dermatitis (NICE TA82)

NICE TA82 - Tacrolimus and pimecrolimus for atopic eczema 

MHRA Drug Safety Update - Tacrolimus ointment (Protopic): possible risk of malignancies including lymphomas and skin cancers

Erectile dysfunction

Erectile Dysfunction

Erectile Dysfunction - when supplied through Specialist Sexual Health Services

Benign Prostatic Hyperplasia (NICE TA273 - terminated appraisal)

NICE TA273 - Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal)

For treating premenopausal women at high risk of breast cancer unless they have a past history or may be at increased risk of thromboembolic disease or endometrial cancer.

Treatment of neuropathic pain in palliative care

Chronic severe pain in adults